European Committee for Treatment & Research in Multiple Sclerosis

Startseite
Schweiz
Basel
European Committee for Treatment & Research in Multiple Sclerosis

We’re the world’s largest professional organisation dedicated to the understanding and treatment of multiple sclerosis.

SAVE THE DATE: MSMilan2023, the 9th joint ECTRIMS-ACTRIMS meeting, will be held as a hybrid event on 11–13 October in Milan, Italy

09/03/2026

💬 𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐒𝐢𝐥𝐞𝐧𝐜𝐞: 𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐘𝐨𝐮𝐧𝐠 𝐀𝐝𝐮𝐥𝐭𝐬 𝐰𝐢𝐭𝐡 𝐌𝐒

As part of , we are highlighting the important work being done by the Supporting Partners of ECTRIMS Patient Community Day.

Today we are featuring a blog from MS Together, which addresses an often overlooked topic in MS research and care: the relationship between multiple sclerosis and the menstrual cycle.

To help close this knowledge gap, MS Together is supporting and contributing to new research exploring how hormonal changes may affect MS symptoms. Alongside this research, they recently hosted an educational webinar bringing together researchers and clinicians to share emerging evidence, answer questions, and empower people with knowledge about their bodies and their condition.

Open conversations and patient-focused research like this are essential to ensuring that the real experiences of people living with MS help shape future care and understanding.

📖 Read the full blog here: https://bit.ly/4rWRGSs

Throughout this month, we will continue showcasing the work of our 𝟰𝟬+ 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗗𝗮𝘆 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗣𝗮𝗿𝘁𝗻𝗲𝗿, highlighting the resources, research, and support they provide to people living with MS around the world.

08/03/2026

🌍 Happy International Women’s Day! 💜

In celebration of International Women's Day, we are happy to announce that applications are officially OPEN for the 2026 Rachel Horne Prize for Women’s Research in MS.

This prestigious US$40,000 award honours the vital contributions of women scientists to the field of neuroimmunology.

🧠 Focus for 2026: This year, the prize will recognise a senior woman neurologist or neuroscientist for her outstanding leadership, career-long achievements, and impact in advancing MS research.

📌 Why Apply? The winner will be celebrated at MSToronto, the 10th Joint ACTRIMS-ECTRIMS Meeting, held in Toronto this October. This is a unique opportunity to gain international recognition for your dedication to the MS community.

💡 How to Apply: Submit a two-page application covering:

✅ Your career context and leadership achievements
✅ Why you should be considered for the prize
✅ Your vision for the future evolution of MS research

🔗 Apply here ➡️ https://bit.ly/4kSLbx7

📅 𝗗𝗲𝗮𝗱𝗹𝗶𝗻𝗲: 𝟭𝟮 𝗝𝘂𝗻𝗲 𝟮𝟬𝟮𝟲

The prize is made possible by the generosity of the Horne Family Charitable Foundation and is supported by iWiMS, ECTRIMS, and the Americas Committee for the Treatment and Research in MS (ACTRIMS).

🏷️ Help us celebrate the women leading the way in science! Tag a deserving senior researcher or share this opportunity to inspire the global MS community.

04/03/2026

The February 2026 (Volume 32, Number 2) issue of the Multiple Sclerosis Journal (MSJ) is out! Publication includes future perspectives, "Controversies in MS", original research, case report, and more.

Read the publication: https://journals.sagepub.com/toc/msja/32/2

This journal is proudly supported by ECTRIMS and other partner organisations.

European Committee for Treatment & Research in Multiple Sclerosis | Americas Committee for Treatment & Research in Multiple Sclerosis ( ACTRIMS) | Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) | Latin America Committee on Treatment and Research of Multiple Sclerosis (Lactrims)| Rehabilitation in Multiple Sclerosis (RiMS) | European Charcot Foundation

03/03/2026

Best of : Pathogenesis Highlight

🔎 In a prospective study, led by Professor Alberto Ascherio from Harvard T.H. Chan School of Public Health, of over 10 million US military personnel, higher vitamin D levels strongly reduced MS risk in White individuals—supporting the potential of vitamin D supplementation for prevention. In Black individuals, the effect was less pronounced, pointing to additional biological mechanisms.

📌 Explore the Pathogenesis Track and all highlights in the Best of ECTRIMS 2025 Slide Deck on myECTRIMS.

Download the Slides ➡️ https://bit.ly/4qWo46i

RiMS - Rehabilitation in Multiple Sclerosis

02/03/2026

🌍 𝗠𝗮𝗿𝗰𝗵 𝗶𝘀 #𝗠𝗦𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀𝗠𝗼𝗻𝘁𝗵🧡

At 𝐄𝐂𝐓𝐑𝐈𝐌𝐒, this month is about shining a light on the strength, resilience, and collaboration that drives the global MS community forward.

We are proud to work alongside more than 𝟰𝟬 𝐒𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬 of Patient Community Day — a diverse network of patient advocacy organisations and institutions dedicated to supporting people living with multiple sclerosis. Every day, these organisations provide trusted information, practical resources, community connection, and vital support to individuals and families affected by MS.

Throughout March, we will be showcasing the incredible work of our Supporting Partners across our advocacy blog and newsletters — highlighting their initiatives, resources, and the impact they make in communities around the world.

Together, we are stronger.
Together, we amplify patient voices.
Together, we advance awareness and education in .

Learn more about our Supporting Partners here: https://bit.ly/4tZm00l

Stay tuned as we use this month to celebrate the organisations helping to empower the .

26/02/2026

Rehabilitation is a personalised process of learning and adaptation that empowers individuals living with MS to maximise independence, participation and quality of life.

Recorded at during the joint meeting with RiMS (Rehabilitation in Multiple Sclerosis), this episode explores why rehabilitation should be embedded in MS care as a form of “prehabilitation”.

Prof. Roshan das Nair from Sintef Digital and Dr. Blanca De Dios Perez, PhD from University of Nottingham speak with host Brett Drummond about:

🔹 Vocational rehabilitation and staying in work
🔹 Mental health as proactive care
🔹 Digital tools for cognitive screening
🔹 Implementation challenges in real-world healthcare
🔹 Building a “community of care” beyond the clinic

Rehabilitation connects clinical care to daily life — and empowers people living with MS to take an active role in managing their disease.

🎧 Listen now — links in the comments.

MStranslate

25/02/2026

📩 Stay at the forefront of Multiple Sclerosis research with ECTRIMS

Subscribe to our newsletter for exclusive updates on:

🏛️ Upcoming Congresses
🎓 Educational Milestones
🔬 Latest Clinical Breakthroughs in MS

Be the first to know what’s next for the global MS community—delivered straight to your inbox, completely free.

Join the community today: 🔗 https://bit.ly/4pgmkEp

19/02/2026

ECTRIMS and the National Multiple Sclerosis Society are pleased to announce the appointment of four distinguished experts to the International Advisory Committee on Clinical Trials in Multiple Sclerosis (IACCTMS). The Committee provides perspective and guidance on planning and implementing clinical trials for the treatment of .

Joining the Committee as of 1 January 2026:

- Ethel Ciampi, MD, Pontificia Universidad Católica de Chile (Chile)
- Kate Fitzgerald, PhD, The Johns Hopkins University (United States)
- Pascal Sati, PhD, Cedars-Sinai Health System (United States)
- Heinz Wiendl, MD, Universitätsklinikum Freiburg (Germany)

These appointments underscore the Committee’s momentum in advancing innovative, patient-centred clinical research, reinforcing its role in shaping the future of MS trials through cross-disciplinary and international expertise.

The Committee extends its sincere appreciation to the following members who have completed their terms:

- Frederik Barkhof, MD, PhD, UCL (United Kingdom)
- Jorge Correale, MD, Raúl Carrea Institute for Neurological Research (Argentina)
- Marcia Finlayson, PhD, Queen's University (Canada)
- Amber Salter, PhD, University of Texas Southwestern Medical Center (United States)

Read the full press release: https://ectrims.eu/press/international-advisory-committee-on-clinical-trials-in-ms-welcomes-new-members/

18/02/2026

From Winter School collaboration to peer-reviewed publication 🎉

A project initiated at the 2024 ECTRIMS Winter School in Innsbruck has now been published in the Multiple Sclerosis Journal.

👉Read it here: https://bit.ly/4akZuXR

First-authored by Roxanne Pretzsch, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and Universitätsspital Basel (USB), this meta-regression of randomised controlled trials (RCTs) shows that neurofilament light chain (NfL) is a promising biomarker for monitoring treatment response in people with multiple sclerosis (MS).

Across 15 RCTs – 9 in relapsing MS and 6 in progressive MS – treatment effects on serum/plasma NfL demonstrated moderate associations with MRI lesion activity, annualised relapse rate and disability worsening.

This publication reflects the value of the ECTRIMS Winter School as both an educational initiative and a platform that fosters collaboration and research among early-career investigators.

17/02/2026

🦠What role does Epstein–Barr virus play in the development of multiple sclerosis?

👉 Read our latest Spotlight here: https://bit.ly/4rBMKlh

This article explores how EBV infection may contribute to MS pathogenesis — and why the timing of infection matters.

“Epidemiological data suggest that EBV is a 𝘤𝘰𝘯𝘥𝘪𝘤𝘪𝘰 𝘴𝘪𝘯𝘦 𝘲𝘶𝘢 𝘯𝘰𝘯 for the development of MS, but it is not sufficient on its own. So, what are the other factors?” says Professor Christian Münz of the Universität Zürich.

“In the end, it would be necessary to have a vaccination strategy against EBV”, adds Professor Tobias Derfuss of the Universität Basel. “Demonstrating that such strategies can reduce MS risk would provide the strongest evidence for a causal link between EBV and MS.”

✍️ The ECTRIMS Spotlight Series is curated and authored by our Scientific Content Writer, Stefania De Vito, PhD.

16/02/2026

| Beyond the Congress

We hope you have enjoyed exploring the Best of Slide Decks and found it valuable in your daily practice. This easy-to-access resource showcases the very best of the science presented in Barcelona.

📥 Keep strengthening the MS community—download and share the slides with your colleagues and peers via myECTRIMS ➡️ https://my.ectrims.eu/bestofslidedecks

12/02/2026

🎧 𝐂𝐚𝐧 𝐧𝐞𝐰 𝐭𝐫𝐢𝐚𝐥 𝐝𝐚𝐭𝐚 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐞 𝐨𝐮𝐭𝐥𝐨𝐨𝐤 𝐟𝐨𝐫 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐯𝐞 𝐌𝐒?

New data presented last week at ACTRIMS Forum 2026 on fenebrutinib suggest BTK inhibition may help bridge that gap – targeting peripheral immune activity and compartmentalised CNS processes driving progression.

In our latest podcast episode, FENtrepid trial leads, Prof. Amit Bar-Or from University of Pennsylvania and Dr. Stephen Hauser from UCSF, speak with host Brett Drummond of MStranslate about why BTK inhibition uniquely targets the cells most implicated in chronic MS progression.

𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:

• Spotify: https://bit.ly/4qq9bcb
• Apple: https://apple.co/4bKafEh
• Website: https://bit.ly/4tjq1MN

Unity Health Toronto, Queen Mary University of London, Università di Genova, Universitätsmedizin Göttingen - UMG, Fraunhofer ITEM, Universität Basel, OhioHealth, Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB)

Adresse

Reinacherstrasse 131
Basel
4053

Telefon

+41616867777

Webseite

http://www.ectrims.eu/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Committee for Treatment & Research in Multiple Sclerosis erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.